Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation

People with opioid use disorders are overrepresented in correctional facilities, and are at high risk of opioid overdose. Despite the fact that buprenorphine/naloxone is the first line treatment for people with opioid use disorder, there are often institutional, clinical, and logistical barriers to...

Descripción completa

Detalles Bibliográficos
Autores principales: Regenstreif, Lori, Sadik, Marina, Beaulieu, Erin, Bodkin, Claire, Kiefer, Lori, Guenter, Dale, Lee, Patsy W. P., Kouyoumdjian, Fiona G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889394/
https://www.ncbi.nlm.nih.gov/pubmed/35235073
http://dx.doi.org/10.1186/s40352-022-00174-w
_version_ 1784661393390174208
author Regenstreif, Lori
Sadik, Marina
Beaulieu, Erin
Bodkin, Claire
Kiefer, Lori
Guenter, Dale
Lee, Patsy W. P.
Kouyoumdjian, Fiona G.
author_facet Regenstreif, Lori
Sadik, Marina
Beaulieu, Erin
Bodkin, Claire
Kiefer, Lori
Guenter, Dale
Lee, Patsy W. P.
Kouyoumdjian, Fiona G.
author_sort Regenstreif, Lori
collection PubMed
description People with opioid use disorders are overrepresented in correctional facilities, and are at high risk of opioid overdose. Despite the fact that buprenorphine/naloxone is the first line treatment for people with opioid use disorder, there are often institutional, clinical, and logistical barriers to buprenorphine/naloxone initiation in correctional facilities. Guided by the knowledge-to-action framework, this knowledge translation project focused on synthesizing knowledge and developing a tool for buprenorphine/naloxone initiation that was tailored to correctional facilities, including jails. This information and tool can be used to support buprenorphine/naloxone access for people in correctional facilities, in parallel with other efforts to address barriers to treatment initiation in correctional facilities.
format Online
Article
Text
id pubmed-8889394
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-88893942022-03-02 Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation Regenstreif, Lori Sadik, Marina Beaulieu, Erin Bodkin, Claire Kiefer, Lori Guenter, Dale Lee, Patsy W. P. Kouyoumdjian, Fiona G. Health Justice Short Report People with opioid use disorders are overrepresented in correctional facilities, and are at high risk of opioid overdose. Despite the fact that buprenorphine/naloxone is the first line treatment for people with opioid use disorder, there are often institutional, clinical, and logistical barriers to buprenorphine/naloxone initiation in correctional facilities. Guided by the knowledge-to-action framework, this knowledge translation project focused on synthesizing knowledge and developing a tool for buprenorphine/naloxone initiation that was tailored to correctional facilities, including jails. This information and tool can be used to support buprenorphine/naloxone access for people in correctional facilities, in parallel with other efforts to address barriers to treatment initiation in correctional facilities. Springer Berlin Heidelberg 2022-03-02 /pmc/articles/PMC8889394/ /pubmed/35235073 http://dx.doi.org/10.1186/s40352-022-00174-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Short Report
Regenstreif, Lori
Sadik, Marina
Beaulieu, Erin
Bodkin, Claire
Kiefer, Lori
Guenter, Dale
Lee, Patsy W. P.
Kouyoumdjian, Fiona G.
Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
title Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
title_full Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
title_fullStr Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
title_full_unstemmed Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
title_short Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
title_sort buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889394/
https://www.ncbi.nlm.nih.gov/pubmed/35235073
http://dx.doi.org/10.1186/s40352-022-00174-w
work_keys_str_mv AT regenstreiflori buprenorphinenaloxoneaccessforpeoplewithopioidusedisorderincorrectionalfacilitiestakingstepstosupportknowledgetranslation
AT sadikmarina buprenorphinenaloxoneaccessforpeoplewithopioidusedisorderincorrectionalfacilitiestakingstepstosupportknowledgetranslation
AT beaulieuerin buprenorphinenaloxoneaccessforpeoplewithopioidusedisorderincorrectionalfacilitiestakingstepstosupportknowledgetranslation
AT bodkinclaire buprenorphinenaloxoneaccessforpeoplewithopioidusedisorderincorrectionalfacilitiestakingstepstosupportknowledgetranslation
AT kieferlori buprenorphinenaloxoneaccessforpeoplewithopioidusedisorderincorrectionalfacilitiestakingstepstosupportknowledgetranslation
AT guenterdale buprenorphinenaloxoneaccessforpeoplewithopioidusedisorderincorrectionalfacilitiestakingstepstosupportknowledgetranslation
AT leepatsywp buprenorphinenaloxoneaccessforpeoplewithopioidusedisorderincorrectionalfacilitiestakingstepstosupportknowledgetranslation
AT kouyoumdjianfionag buprenorphinenaloxoneaccessforpeoplewithopioidusedisorderincorrectionalfacilitiestakingstepstosupportknowledgetranslation

Ejemplares similares